unituxin
united therapeutics europe ltd - dinutuximab - neuroblastom - antineoplastična sredstva - unituxin je indicirano za zdravljenje z visokim tveganjem neuroblastoma pri bolnikih, starih 12 mesecev, da 17years, ki so predhodno prejeli indukcijska kemoterapija in doseči vsaj delni odgovor, sledi myeloablative terapije in avtologna izvornih celic presaditev (asct). uporablja se v kombinaciji z granulocitnim makrofagom, ki spodbuja kolonijo (gm-csf), interlevkin-2 (il-2) in izotretinoin.
kalcij/vitamin d3 lek 1000 mg/880 i.e. žvečljive tablete
holekalciferol (vitamin d3); kalcij - žvečljiva tableta - holekalciferol (vitamin d3) 880 i.e. / 1 tableta kalcij1000 i.e. / 1 tableta; kalcij 1000 i.e. / 1 tableta - kalcij, kombinacije z vitaminom d in/ali drugimi učinkovinami
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.
rispolux neo 2 mg orodisperzibilni filmi
lek d.d. - risperidon - orodisperzibilni film - risperidon 2 mg / 1 od film - risperidon
rispolux neo 3 mg orodisperzibilni filmi
lek d.d. - risperidon - orodisperzibilni film - risperidon 3 mg / 1 od film - risperidon
rispolux 0,25 mg filmsko obložene tablete
filmsko obložena tableta - risperidon
rispolux 1 mg filmsko obložene tablete
filmsko obložena tableta - risperidon
rispolux 1 mg filmsko obložene tablete
filmsko obložena tableta - risperidon
rispolux 1 mg filmsko obložene tablete
filmsko obložena tableta - risperidon
rispolux 2 mg filmsko obložene tablete
filmsko obložena tableta - risperidon